

This is a pre-copyedited, author-produced PDF of an article accepted for publication in The Journal of Clinical Endocrinology & Metabolism following peer review. The version of record Grace Mengqin Ge, Miriam T Y Leung, Kenneth K C Man, Wing Cheong Leung, Patrick Ip, Gloria H Y Li, Ian C K Wong, Annie W C Kung, Ching-Lung Cheung, Maternal Thyroid Dysfunction During Pregnancy and the Risk of Adverse Outcomes in the Offspring: A Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 12, December 2020, Pages 3821–3841 is available online at: <https://doi.org/10.1210/clinem/dgaa555>.

1 **Title:**

2 Maternal thyroid dysfunction during pregnancy and the risk of adverse outcomes in the  
3 offspring: a systematic review and meta-analysis

4 **Authors:**

5 Grace Mengqin Ge<sup>1</sup>, Miriam T. Y. Leung<sup>1</sup>, Kenneth K. C. Man<sup>1, 2</sup>, Wing Cheong Leung<sup>3</sup>,  
6 Patrick Ip<sup>4</sup>, Gloria H.Y. Li<sup>1, 5</sup>, Ian C. K. Wong<sup>1, 2</sup>, Annie W.C. Kung<sup>6</sup>, Ching-Lung Cheung<sup>1\*</sup>

7 **Affiliations:**

8 1. Centre for Safe Medication Practice and Research, Department of Pharmacology and  
9 Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong  
10 Special Administrative Region, China

11 2. Research Department of Practice and Policy, UCL, School of Pharmacy, London, UK

12 3. Department of Obstetrics and Gynecology, Kwong Wah Hospital, Hong Kong

13 4. Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The  
14 University of Hong Kong, Hong Kong Special Administrative Region, China

15 5. Department of Health Technology and Informatics, The Hong Kong Polytechnic University,  
16 Hung Hom, Hong Kong

17 6. Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong,  
18 Hong Kong Special Administrative Region, China

19

20

21

22 \*Corresponding author:

23 Ching-Lung Cheung, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of  
24 Medicine

25 Address: 2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Hong  
26 Kong SAR, China

27 Email: lung1212@hku.hk

28 **Keywords:**

29 gestation, child development, offspring, pregnancy, thyroid, neurodevelopmental disorders

30

31 **ABSTRACT**

32 **Context:** Previous studies suggested a potential link of maternal thyroid dysfunction with  
33 adverse neurocognitive outcomes and impaired development of internal organs in offspring.

34 **Objective:** To review the association between maternal thyroid dysfunction and the risk of  
35 adverse outcomes in offspring.

36 **Data Sources:** PubMed, EMBASE and Cochrane Library.

37 **Study Selections:** Eligible studies reported the association between maternal thyroid hormone  
38 function and the risk of adverse outcomes in their children.

39 **Data Extraction:** Reviewers extracted data on study characteristics and results independently.

40 **Data Synthesis:** Estimates were pooled and reported as odds ratio (OR) with 95% confidence  
41 interval (CI).  $I^2$  tests were applied to assess the heterogeneity across studies.

42 **Results:** We identified 29 eligible articles and found an association between maternal  
43 hyperthyroidism and attention deficit hyperactivity disorder (ADHD) (OR: 1.18, 95% CI: 1.04  
44 - 1.34,  $I^2 = 0\%$ ) and epilepsy (OR: 1.19, 95% CI: 1.08 - 1.31,  $I^2 = 0\%$ ) in offspring; as well as  
45 an association of maternal hypothyroidism with increased risk of ADHD (OR: 1.14, 95% CI:  
46 1.03 - 1.26,  $I^2 = 25\%$ ), autism spectrum disorder (OR: 1.41, 95% CI: 1.05 - 1.90,  $I^2 = 63\%$ ) and  
47 epilepsy (OR: 1.21, 95% CI: 1.06 - 1.39,  $I^2 = 0\%$ ) in offspring.

48 **Conclusion:** Routine measurement and timely treatment on thyroid function should be  
49 considered for pregnant women.

## 50 1. INTRODUCTION

51 Thyroid dysfunction is among the most prevalent endocrine disorders during pregnancy <sup>1,2</sup>.  
52 Hyperthyroidism occurs in about 0.2% of pregnant women, with Graves' disease being the  
53 major underlying cause <sup>3</sup>. Maternal hyperthyroidism is associated with severe adverse effects  
54 in both mother and fetus, including pre-eclampsia, preterm delivery, heart failure, and in-utero  
55 growth retardation (IUGR) <sup>4,5</sup>. Conversely, the incidence of hypothyroidism in pregnancy is  
56 estimated to be from 0.3% to 3%, and it is particularly common in regions with iodine  
57 deficiency <sup>1</sup>. Maternal hypothyroidism is associated with an increased risk of IUGR,  
58 miscarriage, pre-eclampsia, placental abruption, and fetal death <sup>1,6,7</sup>. In addition to  
59 hyperthyroidism and hypothyroidism, as high as 18% <sup>8</sup> of pregnant women are tested positive  
60 for thyroid peroxidase antibody (TPO-Ab) or thyroglobulin antibody (TgAb). TPO-Ab  
61 positivity regulates the effect of maternal thyroid status unfavourably on pregnancy and the  
62 developing fetus <sup>8,9</sup>. Thus, maintaining a normal thyroid status in pregnancy is important for  
63 both the mother and the offspring.

64

65 The growth and development of the fetus are totally dependent on maternal thyroid hormones  
66 until the onset of fetal thyroid function near mid-gestation <sup>10</sup>. Thus, the transferral of maternal  
67 thyroid hormones to the developing fetus is critical during the early stage of pregnancy <sup>10-12</sup>.  
68 The hypothesis of fetal programming <sup>10,13</sup> suggested that maternal thyroid dysfunction can  
69 disturb early fetal brain development and lead to subsequent onset of neurodevelopmental  
70 disorders during the childhood of the offspring. This makes it biologically plausible to  
71 investigate the potential association between maternal thyroid dysfunction during pregnancy  
72 and the long-term health outcome of the offspring <sup>14,15</sup>. Moreover, since the thyroid hormone  
73 receptor is widely expressed in multiple tissues, abnormal maternal thyroid status may also  
74 lead to non-neurodevelopmental disorders in the offspring, such as metabolic or endocrine

75 disorders <sup>16,17</sup>, impaired cardiovascular function <sup>18,19</sup>, and respiratory system <sup>20,21</sup>. Although  
76 maternal thyroid status may have a profound impact on the offspring, no systematic reviews  
77 were conducted to evaluate the relationship.

78

79 Therefore, we conducted a systematic review and meta-analysis of published studies to review  
80 and meta-analyze the association between maternal thyroid dysfunction during pregnancy and  
81 the risk of various adverse outcomes in the offspring.

82

83

## 84 **2. METHODS**

85 This systematic review was reported following The Preferred Reporting Items for Systematic  
86 Reviews and Meta-Analyses (PRISMA) guidelines<sup>22</sup> in Appendix 1 (<https://osf.io/k9jpf><sup>23</sup>).

87

### 88 **2.1 Study search**

89 We performed a systematic literature search in PubMed, EMBASE and Cochrane Library from  
90 inception to 1<sup>st</sup> November 2019, with an updated search conducted on 1<sup>st</sup> February 2020.  
91 Articles from previous reviews or included studies were also reviewed. No restrictions on study  
92 design or language were applied in the search, but only original research studies published in  
93 peer-reviewed journals were included. The search strategy was developed for PubMed and  
94 applied to other databases. The keywords were developed based on 3 concepts: namely (i)  
95 mothers and pregnancy, (ii) thyroid hormone status, and (iii) offspring. The full predefined  
96 search terms and search strategy are provided in the Supplementary Table 1 (<https://osf.io/k9jpf>  
97 <sup>23</sup>).

98

### 99 **2.2 Study selection and data extraction**

100 Only full-text articles reporting the association between maternal thyroid hormone function  
101 during pregnancy and the risk of adverse outcomes in their children were included in the  
102 present systematic review and meta-analysis. Such adverse outcomes included  
103 neurodevelopmental disorders [attention deficit hyperactivity disorder (ADHD), autism  
104 spectrum (ASD), epilepsy, language and speech impairment, depression, schizophrenia, and  
105 cerebral palsy], and other clinically diagnosed outcomes. However, markers of these clinical  
106 outcomes, such as fasting glucose and blood pressure, were excluded from this systematic

107 review and meta-analysis. Whereas, studies related to the thyroid function of the offspring  
108 which measured levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and TPO-  
109 Ab were included. Non-human studies, commentary reviews or descriptive studies without  
110 adequate statistical analysis were excluded.

111

112 The titles and abstracts of the included articles were screened by two independent researchers  
113 (GG and ML). The two authors (GG and ML) independently decided on the inclusion and  
114 exclusion of the studies and conducted data extraction. Discrepancies were resolved by  
115 consensus. Information in the data extraction form included year and country of the publication,  
116 study design, sample size, exposure timing, maternal thyroid status, child outcomes with  
117 measurement tools, age of the children at assessment, summary statistics, and variables used  
118 for potential confounder adjustment. Relative risk (RR), incidence rate ratio (IRR) or  
119 comparable statistics from the fully adjusted model were extracted from each included study.  
120 Since the prevalence of clinical outcomes in offspring are all  $< 10\%$ , odds ratio (OR) is similar  
121 to and considered as comparable to RR. For duplicated studies using the same cohort, the study  
122 with a larger sample size was included in the meta-analysis. As Andersen et al. 2018<sup>15</sup> is an  
123 update of Andersen et al. 2013<sup>24</sup> and Andersen et al. 2014<sup>25</sup> with different study design and  
124 smaller sample size, Andersen et al. 2018<sup>15</sup> was excluded from the systematic review and  
125 meta-analysis.

126

### 127 **2.3 Quality assessment**

128 The quality of the included studies was assessed using The Newcastle-Ottawa Scale (NOS) by  
129 two authors (GG and ML) independently. The NOS consists of three domains (selection,

130 comparability, and outcome), and provides a summary measure of quality for each study.  
131 Disagreements were resolved through discussion with IW and CLC.

132

## 133 **2.4 Data analysis**

134 All included studies were described narratively and presented in Table 1. Pooled OR was  
135 calculated using the inverse variance weighting model. Meta-analysis was conducted when  
136 data of two or more studies investigating the same exposure and outcome were available. The  
137 original studies' definition of maternal hyperthyroidism, hypothyroidism and  
138 hypothyroxinemia was adopted in this meta-analysis. Maternal thyroid parameters (FT4 and  
139 TSH) were fitted as continuous variables and meta-analyzed if they had the same unit (e.g. per  
140 SD). Where multiple cut-offs of FT4 or TPO-Ab were measured, we included results derived  
141 from all cut-offs. We extracted OR / HR from the adjusted model when applicable. We  
142 estimated the OR / HR based on the lower confidence limits in the original studies if only data  
143 with one decimal point was available. The heterogeneity of the studies was evaluated using  $I^2$   
144 tests.  $I^2$  no more than 25% represented low heterogeneity;  $I^2$  between 25% and 50% represented  
145 moderate heterogeneity;  $I^2$  greater than 50% represented high heterogeneity. The overall effects  
146 were analyzed with a fixed-effects model if the heterogeneity was low; otherwise, a random-  
147 effects model was applied. Forest plots were generated for further visual inspection of  
148 heterogeneity. Statistical analyses were conducted using Review Manager (RevMan 5.3;  
149 Cochrane Collaboration, Oxford, UK).

150

151 **3. RESULTS**

152 **3.1 Study selection**

153 A total of 9975 records were identified by the electronic search engine. After removal of  
154 duplicates, 7914 items were evaluated based on title and abstract screening, of which 151 full-  
155 text articles were assessed for eligibility. Of these, 29 studies <sup>14,16-21,24-45</sup> met our inclusion  
156 criteria and were included in this study. The PRISMA flow diagram summarizing the search  
157 results is presented in Figure 1.

158

159 **3.2 Characteristics of included studies**

160 Study characteristics are summarized and shown in Table 1. All included studies were  
161 observational studies based on population-based prospective birth cohorts or national register-  
162 based retrospective cohorts. Among the 29 studies included, 22 articles investigated the  
163 association between maternal thyroid dysfunction and neurodevelopmental disorders in  
164 offspring. One of these 22 articles, together with the remaining 7 articles, also investigated  
165 non-neurodevelopmental outcomes. In all these 29 studies, the non-exposure group comprised  
166 pregnant mothers without thyroid dysfunction. Estimates of maternal thyroid status and  
167 offspring outcomes extracted from these 29 studies are provided in Tables 2 - 5. Pooled  
168 estimates and the forest plots are provided in Figures 2 - 4. The corresponding funnel plots are  
169 provided in Supplementary Figures 1 - 3 (<https://osf.io/k9jpf> <sup>23</sup>).

170

171 **3.3 Neurodevelopmental disorders in the offspring (N = 22)**

172 Most studies (N = 17) were conducted in European countries except five were conducted in  
173 India (N =1), Israel (N =1), and the United States (N = 3). There are 18 cohort studies and 4



174 case-control studies. Maternal thyroid dysfunctions discussed were hyperthyroidism,  
175 hypothyroidism, hypothyroxinemia and levels of maternal thyroid hormone [including TSH,  
176 FT4, and thyroperoxidase antibodies positive (TPO-Abs+)].

177

### 178 **3.3.1 Hyperthyroidism**

179 Seven studies investigated hyperthyroidism as exposure (Table 2), with ADHD ( $n_{\text{study}} = 2$ ;  
180  $n_{\text{sample size}} = 15422$ )<sup>25,29</sup>, ASD ( $n_{\text{study}} = 2$ ;  $n_{\text{sample size}} = 14204$ )<sup>25,26</sup>, epilepsy ( $n_{\text{study}} = 2$ ;  $n_{\text{sample size}}$   
181  $= 25495$ )<sup>14,24</sup>, and schizophrenia ( $n_{\text{study}} = 2$ ;  $n_{\text{sample size}} = 4638$ )<sup>14,28</sup> in offspring as the outcomes.  
182 The pooled OR of offspring ADHD, ASD, epilepsy, and schizophrenia was 1.18 (95% CI: 1.04  
183 - 1.34), 1.17 (95% CI: 0.96 - 1.42), 1.19 (95% CI: 1.08 - 1.31), and 0.96 (95% CI: 0.53 - 1.72),  
184 respectively. The heterogeneity was estimated to be low ( $I^2 = 0\%$ ) in all outcomes. (Figure 2,  
185 Supplementary Figure 1 [<https://osf.io/k9jpf>]<sup>23</sup>)

186

187 Only one study investigated the association between maternal hyperthyroidism and cerebral  
188 palsy, revealing a null association<sup>42</sup> (Table 2). Meta-analysis was not performed for this  
189 outcome.

190

### 191 **3.3.2 Hypothyroidism**

192 Among all maternal thyroid status, maternal hypothyroidism was the most frequently studied  
193 ( $N = 12$ ). There are 4 ( $n_{\text{sample size}} = 32827$ ), 5 ( $n_{\text{sample size}} = 419878$ ), 2 ( $n_{\text{sample size}} = 12465$ ), 2  
194 ( $n_{\text{sample size}} = 2780$ ), and 2 studies ( $n_{\text{sample size}} = 29070$ ) investigating ADHD<sup>25,29,37,38</sup>, ASD<sup>25-</sup>  
195 <sup>27,34,37</sup>, epilepsy<sup>14,24</sup>, schizophrenia<sup>14,28</sup>, and cerebral palsy<sup>37,42</sup> as the clinical outcomes  
196 respectively (Table 3). The pooled OR for offspring ADHD, ASD, epilepsy, schizophrenia,

197 and cerebral palsy was 1.14 (95% CI: 1.03 - 1.26), 1.41 (95% CI: 1.05 - 1.90), 1.21 (95% CI:  
198 1.06 - 1.39), 3.02 (95% CI: 0.26 - 35.51), and 0.95 (95% CI: 0.64 - 1.40), respectively, with  
199 low (ADHD:  $I^2 = 25\%$ ; epilepsy / cerebral palsy:  $I^2 = 0\%$ ), to high (ASD:  $I^2 = 63\%$ ,  
200 schizophrenia:  $I^2 = 86\%$ ) heterogeneity detected for each outcome (Figure 3, Supplementary  
201 Figure 2 [<https://osf.io/k9jpf> <sup>23</sup>]).

202

203 Only one study by Frank et al. <sup>33</sup> investigated language and speech impairment as the clinical  
204 outcome but null association was observed in the study (HR: 0.75, 95% CI: 0.38 - 1.43, Table  
205 3).

206

207 The definition of hypothyroidism in the included studies were mainly overt hypothyroidism.  
208 Only three studies performed an exploratory analysis of maternal subclinical hypothyroidism  
209 and investigated offspring ASD <sup>26</sup>, schizophrenia <sup>28</sup>, and ADHD <sup>39</sup> as the clinical outcomes,  
210 but null association was observed.

211

### 212 **3.3.3 Hypothyroxinemia**

213 Five studies investigated the association between maternal hypothyroxinemia and offspring  
214 neurodevelopmental disorders (Table 4). Three studies investigated ADHD as a clinical  
215 outcome. Modesto et al. <sup>39</sup> found children exposed to maternal hypothyroxinemia during  
216 pregnancy had higher ADHD scores compared with non-exposed children ( $\beta : 0.07$ , 95% CI:  
217 0.003 - 0.14). Similarly, Oostenbroek et al. <sup>40</sup> found maternal hypothyroxinemia with FT4 < 5<sup>th</sup>  
218 percentile was associated with a 1.70-fold (95% CI: 1.01 - 2.86) increase in odds of teacher-  
219 reported ADHD, although a null association was observed when parent-reported ADHD was

220 used as the outcome. Vermiglio et al. <sup>44</sup> reported a significantly higher prevalence of ADHD  
221 among the offspring of mothers with hypothyroxinemia in the moderately iodine-deficient  
222 region.

223

224 Only one single study was conducted for the association of maternal hypothyroxinemia with  
225 offspring ASD and schizophrenia (Table 4). Roman et al. <sup>43</sup> reported severe maternal  
226 hypothyroxinemia (FT4 < 5<sup>th</sup> percentile) was associated with increased odds of pervasive  
227 developmental problems in offspring (OR: 2.60, 95% CI: 1.30 - 5.18). Gyllenberg et al. <sup>28</sup>  
228 reported a positive association between maternal hypothyroxinemia and offspring  
229 schizophrenia (OR: 1.75, 95% CI: 1.22 - 2.50).

230

### 231 **3.3.4 Thyroid hormone levels**

232 Eleven studies investigated the association between maternal thyroid hormone parameters and  
233 offspring neurodevelopmental disorders (Table 5). Fetene et al. <sup>32</sup> found null association  
234 between maternal TPO-Ab+ with offspring ADHD, but Ghassabian et al. <sup>36</sup> observed an  
235 association between elevated titers of TPO-Abs and the risk of ADHD (OR = 1.77, 95% CI:  
236 1.15-2.72, Table 5). Two studies <sup>26,43</sup> investigated the association of maternal TPO-Ab+ with  
237 offspring ASD ( $n_{\text{sample size}} = 5959$ ), and the pooled OR is 1.30 (95% CI: 0.58 - 2.94,  $I^2 = 60\%$ )  
238 (Figure 4, Supplementary Figure 3 [<https://osf.io/k9jpf> <sup>23</sup>]). Notably, the two studies used  
239 different cut-off points to define TPO-Ab+.

240

241 Four studies investigated the association of maternal FT4 level with offspring ADHD. Chevrier  
242 et al. <sup>30</sup> and Modesto et al. <sup>39</sup> found a null association between maternal FT4 level and offspring

243 scores on ADHD (Table 5). The other two studies<sup>32,40</sup> included offspring ADHD as a binary  
244 outcome and also found the level of maternal FT4 was not associated with ADHD in children.

245

246 Six studies investigated the association of maternal TSH level with offspring ADHD. Chevrier  
247 et al.<sup>30</sup> found doubling in TSH levels was associated with a 0.65 point decrease (95% CI = -  
248 1.26 to -0.04) on the ADHD subscale of the Child Behaviour Checklist (CBCL), but there was  
249 no significant association between maternal TSH level and child's performance on the  
250 Conner's Kiddie Continuous Performance Test (KCPT). Ghassabian et al.<sup>35</sup> reported that per  
251 SD increase in plasma level of TSH was associated with higher CBCL externalizing (ADHD)  
252 scores. On the other hand, Modesto et al.<sup>39</sup> found null association between maternal TSH level  
253 and offspring scores on ADHD using Conner's Parent Rating Scale-Revised Short Form. Three  
254 studies<sup>32,40,41</sup> fitted maternal TSH level as continuous variables and included offspring ADHD  
255 as a binary outcome. Fetene et al.<sup>32</sup> observed null association between maternal TSH level and  
256 offspring ADHD. Similarly, Oostenbroek et al.<sup>40</sup> observed null association between maternal  
257 TSH level and offspring ADHD, either reported by teachers or by parents. However, Pakkila  
258 et al.<sup>41</sup> found an association for each log increase in maternal TSH with ADHD symptoms in  
259 both boys (OR: 1.17, 95% CI: 1.00 - 1.36) and girls (OR: 1.39, 95% CI: 1.07 - 1.80, Table 5).

260

261 Only one single study was conducted for the following comparisons between maternal thyroid  
262 hormone levels and offspring neurodevelopmental disorders. Roman et al.<sup>43</sup> investigated the  
263 association of maternal FT4 and TSH levels with offspring ASD while null association was  
264 observed. Fetene et al.<sup>31</sup> was the only study investigating offspring depression as a clinical  
265 outcome. They reported a null association of maternal TPO-Ab+ and TSH levels with offspring  
266 depression. Meanwhile, a significant association of maternal FT4 level with higher odds of

267 depression in offspring was observed (OR: 1.21, 95% CI: 1.00 - 1.47). Gyllenberg et al.<sup>28</sup>  
268 investigated the association of maternal FT4 and TSH levels with offspring schizophrenia.  
269 They found the odds of schizophrenia decreased by 54% per log unit increase of maternal FT4  
270 (95% CI: 0.31 - 0.94), but the association between log-transformed level of TSH and  
271 schizophrenia was not significant (Table 5).

272

### 273 **3.4 Non-neurodevelopmental outcomes (N = 8)**

274 Since most of the non-neurodevelopmental outcomes were observed in one single study  
275 (Supplementary Table 2, <https://osf.io/k9jpf><sup>23</sup>), meta-analysis was not conducted, and the  
276 individual studies were described in Supplementary Text (<https://osf.io/k9jpf><sup>23</sup>).

277

### 278 **3.5 Quality assessment**

279 Study quality assessments were presented in Appendix 2 (<https://osf.io/k9jpf><sup>23</sup>). Most studies  
280 (accounted for 60% of total included studies) were of good quality except for nine studies. The  
281 overall quality of these nine studies was low because of the small sample size, poor  
282 identification of exposure and outcomes, or they did not adjust for any potential covariates in  
283 the model. Six out of the nine studies were not included in meta-analysis. For the remaining  
284 three, we performed additional sensitivity analyses by removing lower-quality studies in the  
285 meta-analysis. An exception is the association analysis between maternal TPO-Ab+ and  
286 offspring ASD where only two studies were included in the meta-analysis, indicating cautious  
287 interpretation may be required. Similar results were observed in all the sensitivity analyses  
288 when compared to the original analysis without excluding lower-quality studies (Figure 3).

## 289 **4. DISCUSSION**

290 This is a comprehensive systematic review with meta-analysis providing evidence for the  
291 association between maternal thyroid status and various offspring clinical outcomes. In general,  
292 maternal hyperthyroidism during pregnancy was significantly associated with increased risk of  
293 offspring ADHD, epilepsy, and hyperthyroidism. Whereas, maternal hypothyroidism during  
294 pregnancy was significantly associated with increased risk of ADHD, ASD, epilepsy, and  
295 hypothyroidism. These findings suggest that either maternal hyper- or hypo-thyroidism could  
296 affect neurodevelopment and thyroid health in the offspring.

297

### 298 **4.1 Maternal thyroid dysfunction and neurodevelopmental disorders in offspring**

299 Most studies included in this systematic review and meta-analysis studied maternal  
300 hypothyroidism as exposure. Although not a highly prevalent condition during pregnancy,  
301 maternal hypothyroidism is known to be associated with increased risk of spontaneous  
302 miscarriage, stillbirth, and perinatal death. Regarding the ascertainment of thyroid status, 13  
303 out of 22 studies measured maternal exposure using thyroid function test, while the other nine  
304 studies used clinical diagnosis or prescription records from hospitals. The majority of the  
305 studies employed laboratory tests to measure maternal thyroid levels during the first and early  
306 second trimesters. Notably, most studies available did not adjust for treatment status, while this  
307 potential factor can play a role in the association. A recently published article by Rotem et al.  
308 <sup>46</sup>, which is out of our investigation period, examined the association between maternal thyroid  
309 disorders and the risk of ASD in offspring, taking into account gestational thyroid hormone  
310 level and thyroid medications use. They found that maternal thyroid disorders, especially  
311 hypothyroidism, were associated with increased ASD risk in the offspring. This observation is  
312 indeed in line with our meta-analysis, showing hypothyroidism was significantly associated

313 with offspring ASD. Nevertheless, they proposed that the association between maternal thyroid  
314 status and offspring ASD was independent of maternal gestational thyroid hormones and  
315 unaffected by medication treatment. By including a more comprehensive range of confounding  
316 factors and biologically relevant covariates (e.g. thyroxine treatment), future studies are  
317 warranted to re-visit the association between maternal thyroid dysfunction and various health  
318 outcomes in offspring. Together with larger sample size and longer follow-up time, future work  
319 may particularly focus on the underlying mechanisms, which is largely unknown.

320

321 Notably, in the setting of register-based study cohorts using diagnosis codes or prescription  
322 records for exposure measurement, most included studies were unable to identify individuals  
323 with subclinical hypothyroidism. Only three studies investigated the association between  
324 maternal subclinical hypothyroidism and clinical outcomes in offspring while null associations  
325 were reported. The current data did not show a consistent association between subclinical  
326 hypothyroidism during pregnancy and adverse pregnancy outcomes<sup>8,47-49</sup> but this was  
327 observed in a limited number of studies with small sample size. In fact, subclinical  
328 hypothyroidism is more common than overt hypothyroidism<sup>8,50</sup> Future studies are required to  
329 examine individuals with subclinical hypothyroidism. On the other hand, we observed in this  
330 review that there was some evidence of association between maternal hypothyroxinemia and  
331 offspring ADHD, ASD and schizophrenia. To date, treatment for thyroid dysfunction during  
332 pregnancy is still a controversial issue<sup>48,49</sup>. The potential risks of maternal hypothyroxinemia  
333 on the offspring unraveled in this review may raise the awareness of the need to devise an  
334 optimum clinical management strategy for pregnant women, such as levothyroxine treatment.

335

336 The most commonly studied outcome is neurodevelopmental disorders in offspring, and there  
337 is a plausible explanation of the impact of maternal thyroid status during the first and early  
338 stages of second trimesters on the neurodevelopment in offspring<sup>51-53</sup>. The fetal thyroid heavily  
339 depends on the maternal supply of thyroid hormone before the onset of thyroid function in the  
340 fetus which occurs around 16 - 20 weeks of gestation, and there is a significant transfer of  
341 thyroid hormones from the mother to the fetus<sup>10,12</sup>. The supply of thyroid hormone to the fetus  
342 leads to increased FT4 and decreased TSH concentrations from around the eighth week till the  
343 first half of pregnancy in the pregnant mothers, resulting in different reference intervals for  
344 TSH and FT4 when compared with the non-pregnant status<sup>54</sup>. Besides, Oostenbroek et al.<sup>40</sup>  
345 investigated maternal thyroid hormone levels throughout the whole duration of pregnancy.  
346 They partially confirmed early disruption in maternal thyroid function may be associated with  
347 ADHD but found a null association with other behavioral problems. In this systematic review  
348 and meta-analysis, we provided evidence that maternal hyper- and hypo-thyroidism are  
349 associated with increased risk of a range of neurodevelopmental disorders, suggesting that the  
350 impact of maternal thyroid status may not be limited to ADHD only in offspring.

351

352 The impact of maternal thyroid status after the early stage of the second trimester is less  
353 frequently studied. Chevrier et al.<sup>30</sup> was the only one who measured maternal thyroid hormone  
354 during the third trimester. They reported a higher maternal TSH level was associated with a  
355 lower risk of having ADHD symptoms in offspring. Whereas, some studies identified a positive  
356 association between higher maternal thyroid hormone levels in the first two trimesters and  
357 increased risk of ADHD in offspring<sup>35,41</sup>. This indicated a balanced level of maternal thyroid  
358 hormone at each stage of pregnancy would be optimal for fetus neurodevelopment. However,  
359 the presence of abnormal thyroid status in the third trimester could be a marker of abnormal



360 thyroid status in earlier trimesters. Nevertheless, the effect of timing of maternal thyroid  
361 function measurement requires further studies.

362

363

364

## 365 **4.2 Strength and limitations**

366 Previously, three published systematic reviews investigated the association between maternal  
367 thyroid hormone abnormalities and the risk of neurodevelopmental disorders in the offspring  
368 <sup>55-57</sup>. Two systematic reviews examined the relationship between maternal thyroid dysfunction  
369 and psychiatric disorders (mainly focused on ADHD) <sup>58,59</sup>. Compared to these previous reviews,  
370 our study had a wider scope in respect of both the exposure and the outcome. Moreover, we  
371 only included outcomes that are clinically diagnosed or ascertained by well-established  
372 measurement tools. The setting of our inclusion criteria is more likely to produce consistent  
373 and reliable conclusions.

374

375 Nevertheless, there are limitations. First, we observed marginally significant association in the  
376 meta-analysis, which could be due to the limited number of studies, and the small sample size  
377 in each study, echoing the presence of the research gap and arousing the need to have more  
378 studies in this important but underexplored area. Cautious interpretation is also required in the  
379 current meta-analysis. Second, the definitions of thyroid dysfunction were heterogeneous  
380 across studies, as there was no consensus in the definition of thyroid dysfunction during  
381 pregnancy at the time of this current study. Third, the definition of the clinical outcomes was  
382 not standardized in the included studies. Although we only included outcomes that were

383 clinically diagnosed or assessed by validated tools, ten out of 22 studies that examined  
384 neurodevelopmental outcomes in offspring used behavior checklist rather than diagnosis or  
385 prescription records to identify the outcomes. The questionnaires adopted were reported by  
386 parents<sup>30-32,35,36,39-41,43</sup>, teachers<sup>40</sup>, self-report<sup>31,32</sup>, or by clinical observation<sup>44</sup>, leading to the  
387 discrepancy of the estimates. Fourth, the timing for the measurement of offspring outcomes  
388 plays a key role in revealing the association. Outcomes such as schizophrenia and depression  
389 usually develop at a late stage in childhood or even adolescence. Thus, a long follow-up time  
390 is essential to detect the potential association. Fifth, clinical outcomes ascertained using the  
391 diagnosis code or prescription records could lead to overestimation by misclassification. As  
392 these limitations may increase heterogeneity between studies, cautious interpretation is  
393 required regarding the findings of meta-analyses with high heterogeneity.

394

### 395 **4.3 Clinical interpretations**

396 Although measurement of maternal thyroid hormone levels during pregnancy can be used for  
397 determining maternal thyroid status, current guidelines from the American Thyroid  
398 Association and the European Thyroid Association differ in their recommendations regarding  
399 the screening of thyroid hormone during pregnancy<sup>2,50</sup>. The current systematic review and  
400 meta-analysis highlighted the potential association between maternal thyroid dysfunction  
401 during pregnancy and various disorders in the offspring, suggesting the importance of  
402 prevention during pregnancy in maintaining the health of the offspring. To cater for fetal iodine  
403 requirement, increase in maternal thyroid hormone production and renal iodine clearance, there  
404 is an elevated iodine requirement during pregnancy. Having sufficient iodine intake during  
405 pregnancy is one of the effective preventive measures of maternal thyroid dysfunction. In cases  
406 of pregnant mothers who are diagnosed with abnormal thyroid function, they should be

407 promptly treated and carefully monitored throughout pregnancy to avoid hyper- and hypo-  
408 thyroidism. Regarding the thyroid hormone supplementation during pregnancy, a recent  
409 systematic review and meta-analysis <sup>60</sup> of randomized controlled trials (RCTs) and  
410 retrospective studies including 7970 patients demonstrated that LT4 supplementation had  
411 beneficial effects in pregnant women with subclinical hypothyroidism and / or thyroid  
412 autoimmunity by reducing their risks of pregnancy loss and preterm birth. Consistent results  
413 were obtained by subgroup analysis of RCTs. Depending on the types of pregnancy [naturally  
414 conceived pregnancies, versus pregnancy achieved by assisted reproduction technology (such  
415 as in vitro fertilization and intracytoplasmic sperm injection)], LT4 supplementation may  
416 reduce the risk of pregnancy loss or / and preterm birth better in women with thyroid  
417 autoimmunity or subclinical hypothyroidism. On the other hand, a meta-analysis <sup>61</sup> of RCTs  
418 demonstrated that euthyroid women with individualized initial dosages of LT4 had lower risk  
419 of miscarriage, while those with fixed dosages of LT4 showed no significant difference. In  
420 addition, euthyroid women with thyroid autoimmunity given initial LT4 treatment in early  
421 pregnancy had a lower risk of preterm birth when compared with those receiving placebo or  
422 no treatment. According to the aforementioned findings, detailed treatment strategies (such as  
423 timing and dosage of initial treatment) should be developed for pregnant women based on their  
424 types of pregnancy and thyroid status. After such strategies are developed, individualized  
425 therapeutic strategy of LT4 supplementation might be encouraged for pregnant women with  
426 euthyroidism, subclinical hypothyroidism or thyroid autoimmunity. Nevertheless, the number  
427 of RCTs to date is limited, and the sample size of available studies are small. Future large RCTs  
428 are warranted in this area.

429 **5. CONCLUSION**

430 Our review suggested that maternal thyroid dysfunction during pregnancy is a potential risk  
431 factor for neurodevelopmental disorders (including ADHD, ASD, epilepsy), other  
432 cardiometabolic and respiratory conditions, and thyroid dysfunction in offspring during  
433 childhood. Currently, the optimum management strategy of maternal thyroid dysfunction  
434 during pregnancy is still largely unexplored. In view of these findings, routine measurement of  
435 thyroid function test during early pregnancy should be considered for all pregnant women.  
436 Further studies are warranted to delineate the association of thyroid status, especially levels of  
437 anti-TPO antibodies, in pregnancy and fetal outcome.


438 **DISCLOSURE SUMMARY**

439 KKCM is the recipient of the CW Maplethorpe Fellowship and personal fees from IQVIA Ltd.,  
440 unrelated to the submitted work. PI has received funding from the Hong Kong Research Grants  
441 Council, Health & Medical Research Fund and Hong Kong Jockey Club Charities Trust,  
442 unrelated to the submitted work. ICKW reports research funding outside the submitted work  
443 from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong  
444 RGC, and the Hong Kong Health and Medical Research Fund, National Institute for Health  
445 Research in England, European Commission, National Health and Medical Research Council  
446 in Australia, and also received speaker fees from Janssen and Medicine in the previous 3 years,  
447 unrelated to the submitted work. The other authors declare no conflict of interest.

448 **AUTHOR NOTES**


449 CLC contributed to the conception of the work and designed the study. GMG and MTYL  
450 decided on the inclusion and exclusion of studies, and conducted data extraction. GMG  
451 performed the meta-analysis, wrote the first draft of the manuscript, had full access to all the  
452 data in the study and takes responsibility for the integrity of the data and the accuracy of the  
453 data analysis. KKCM, WCL, PI, GHYL, ICKW and AWCK interpreted, critically evaluated,  
454 and improved the study design and manuscript, and shared the responsibility for the final  
455 manuscript and the decision to submit.

**Figure 1. PRISMA flow diagram of included studies**




**Figure 2. Meta-analysis of studies on the association between maternal hyperthyroidism and a. ADHD, b. ASD, c. epilepsy, and d. schizophrenia in the offspring.**


**a. ADHD**




**b. ASD**



**c. epilepsy**




**d. schizophrenia**




**Figure 3. Meta-analysis of studies on the association between maternal hypothyroidism and a. ADHD, b. ASD, c. epilepsy, d. schizophrenia, and e. cerebral palsy in the offspring. Sensitivity analysis was conducted by i.) including or ii.) removing the comparatively lower quality study.**

**a. ADHD**

i.)




ii.) removing Haddow 1999 et al.




**b. ASD**

i.)




ii.) removing George 2014 et al.







### c. epilepsy




### d. schizophrenia



### e. cerebral palsy



**Figure 4. Meta-analysis of studies on the association between maternal TPO-Ab+ and offspring ASD**



**Table 1. Characteristics of studies with maternal thyroid dysfunction exposure and adverse outcomes in the offspring**

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), <i>Measurement kit for laboratory assays</i>	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
1	Brown et al. (2015), Finland	case-control (1,920)	TFT: TSH, FT4, TPO-Ab (1 <sup>st</sup> and early 2 <sup>nd</sup> trimesters), <i>Abbott Diagnostics, Abbott Park, IL</i>	TPO-Ab <sup>+</sup> : 29.62 $\pm$ 4.65 TPO-Ab <sup>-</sup> : 29.22 $\pm$ 5.30	ASD: Dx from FHDR, assessed with the ADI-R	N.A.	no adjusted covariate
2	Grattan et al. (2014), Canada	case-control (998)	self-report maternal history of hypothyroidism with a standardised questionnaire (during pregnancy)	N.A.	CHD: Dx using echocardiography	range 0 to 18, median of 2.7	age and risk of child chromosomal disorder, maternal diabetes mellitus, maternal age, and family history of CHD
3	George et al. (2014), India	case-control (343)	self-report Dx by interview (during pregnancy)	N.A.	ASD: Dx from autism clinic of Child Development Centre, using a Childhood Autism Rating Scale, score over 30	range 2 to 6	antenatal and natal risk factors for autism
4	Gyllenberg et al. (2016), Finland	case-control (2,020)	TFT: TSH, FT4 (1 <sup>st</sup> trimester) <i>Abbott Diagnostics, Abbott Park, IL</i>	cases: 28.5 $\pm$ 5.5 control: 28.2 $\pm$ 5.1	schizophrenia: FHDR, using ICD-10: F20 and ICD-10: F25	N.A.	maternal psychiatric history, maternal smoking, degree of urbanization of birth municipality, birth province, twinning
5	Instanes et al. (2017), Norway	case-control (2,332,657)	Dx based on medical registry diagnosis records from MBRN and NorPD (before or during pregnancy)	N.A.	ADHD: Rx of ADHD medications methylphenidate (ATC code NO6BA04),	> 3	year of birth, parity, mother's age at birth, mother's educational level, mother's marital status, maternal and

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), <i>Measurement kit for laboratory assays</i>	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
					atomoxetine (ATC code N06BA09) and racemic amphetamine (ATC code N06BA01) extracted from the NorPD		paternal use of ADHD medication
6	Andersen et al. (2014), Denmark	cohort (857,014)	Dx & Rx from DNHR and DNPR (before and after delivery)	N.A.	ADHD, ASD: Dx & Rx from DNHR, DPCR and DNPR ADHD: ICD-10: F90; if no Dx then at least two Rx of ADHD medication (ATC N06NA) ASD: ICD-10: F84	range 3 to 18	gender of the child, year of birth of the child, maternal age, maternal origin, maternal residence, maternal marriage status, income, and parity
7	Andersen et al. (2013), Denmark	cohort (1,699,693)	Dx from DNHR (before and after delivery);	N.A.	epilepsy: Dx after the neonatal period, data from DNHR using ICD-8: 345.09–345.99 and ICD-10: G40.0–G41.9	median of 5.3	gender of the child, birth year, maternal age, parity including index pregnancy, maternal marriage status, income, maternal origin, maternal residence, and maternal diagnosis of febrile seizure and/or epilepsy registered in the DNHR
8	Chevrier et al. (2011), U.S.	cohort (287)	TFT: TSH, FT4 (26.9 $\pm$ 3.4 weeks gestation); <i>Siemens Healthcare Diagnostics, Deerfield, IL;</i>	N.A.	ADHD: maternal report on the Attention Problems scale of the CBCL or	5	maternal age, income, employment status at 6 months, country of birth, diet quality index, delivery complications,

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), <i>Measurement kit for laboratory assays</i>	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
					child performance on the KCPT		PPV (Peabody Picture Vocabulary Test) score, child 5minute APGAR, hospitalization at 1 year; the number of children in the home at 1 and 2 years, home density at 2 years, the family structure at 1 year; the season of assessment.
9	Cowett et al. (1975), U.S.	cohort (1,394)	butanol-extractable iodine determination and clinical history (during pregnancy)	N.A.	respiratory distress syndrome: clinical evidence of respiratory distress syndrome (N.A.)	N.A.	no adjusted covariate
10	Eshkoli et al. (2019), Israel	cohort (217,910)	Dx based on the maternal report as well as on a routine review of all computerized medical records from the hospital and ambulatory setting from SUMC (during pregnancy)	hypothyroidism: 30.8 $\pm$ 5 euthyroid: 28.2 $\pm$ 5	pediatric endocrine morbidity: Dx using ICD-9 codes	N.A.	gestational and pregestational diabetes mellitus, chronic, gestational or pre-eclampsia, delivery before 37 weeks of gestation
11	Fetene et al. (2019), U.K.	cohort (2,920)	TFT: TSH, FT4 (1 <sup>st</sup> trimester); <i>Abbott Diagnostics, Abbott Park, IL</i>	28.9 $\pm$ 4.6	depression: DAWBA coded according to parent-reported or self-reported DMS-IV criteria	7.5 for parent-reported depression; 15 for self-reported depression	maternal age, BMI, gender, birth weight, maternal smoking, maternal depression, gestational hypertension, and zinc and iodine intake during pregnancy

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
12	Fetene et al. (2018), U.K.	cohort (2,912)	TFT: TSH, FT4, TPO-Ab (1 <sup>st</sup> trimester); <i>Abbott Diagnostics, Abbott Park, IL</i>	28.9 $\pm$ 4.6	ADHD: DAWBA coded according to parent-reported or self-reported DSM-IV criteria	7.5 for parent-reported ADHD; 15 for self-reported ADHD	maternal age, BMI, sex, gestational hypertension, antenatal depression, maternal smoking, partner smoking, maternal alcohol use, birth weight, maternal iodine, and zinc intake during pregnancy
13	Frank et al. (2019), Norway	cohort (1,204)	Rx records from MBRN and NorPD based on ATC classification System (during pregnancy)	N.A.	language impairment: ICD-10: F80 and parent-reported symptoms of language and communication skill deficits	8	maternal age, educational level, income, parity, BMI at conception, use of folic acid and other supplements, lifetime history of major depression, comedication for somatic and mental comorbidities, and smoking and alcohol use during pregnancy
14	Getahun et al. (2018), U.S.	cohort (397,201)	Dx using ICD-9: 244.X and medication prescribed to treat the condition (during pregnancy);	N.A.	ASD: at least one documented DSM-IV code for ASD on any two separate visits	range 2 to 17	maternal age, education, smoking during pregnancy, prenatal care, parity, year of diagnosis, median household income, child's sex and race/ethnicity
15	Ghassabian et al. (2012), Netherland	cohort (3,139)	TFT: TSH, FT4, TPO-Ab (13.5 $\pm$ 1.8 weeks of gestation);	TPO-Ab <sup>+</sup> : 31.2 $\pm$ 4.3 TPO-Ab <sup>-</sup> : 31.1 $\pm$ 4.3	ADHD: CBCL completed by parents, using scales consistent with	3	child's gender and ethnicity, maternal age, cigarette smoking, and

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
			<i>Vitros ECI Immunodiagnostic System Ortho Clinical Diagnostics, Rochester, NY</i>		diagnostic categories of DSM-IV		time of thyroid sampling during pregnancy
16	Ghassabian et al. (2011), Netherland	cohort (3,736)	TFT: TSH, FT4 (13.3 $\pm$ 1.7 weeks of gestation)	30.9 $\pm$ 4.5	ADHD: CBCL completed by parents, using externalizing (attention problems and aggressive behaviour) scale consistent with diagnostic categories of DSM	1.5 and 3	maternal age, education level, and psychopathology, child's gender, ethnicity, mode of delivery, and gestational age at the time of maternal thyroid sampling
17	Gutvartz et al. (2019), Israel	cohort (217,910)	Dx based on the maternal report as well as medical records from the hospital and/or ambulatory settings, data from SUMC (during pregnancy)	hypothyroidism: 30.8 $\pm$ 5.2 no hypothyroidism: 28.2 $\pm$ 5.7	ADHD, ASD, cerebral palsy: computerized pediatric hospitalization database of SUMC and the computerized perinatal database of the Obstetrics and Gynecology department	< 18	maternal age, birth weight, pre-gestational and gestational diabetes and hypertensive disorders of pregnancy (pregestational, gestational hypertension and pre-eclampsia)
18	Haddow et al. (1999), U.S.	cohort (186)	TFT: TSH, FT4, TPO-Ab (2 <sup>nd</sup> trimester); <i>TSH: Diagnostic Products, LA;</i> <i>FT4: Wallac Oy, Turku, Finland;</i> <i>TPO-Ab: Kronus, San Clemente, Calif;</i>	N.A.	ADHD: the Conners' Continuous Performance Test to measure sustained vigilance and WISC-III scores	8	no adjusted covariate

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
19	Heikkinen et al. (2017), Finland	cohort (3,229)	TFT: thyrotropin, FT4, TPO-Ab, Tg-Abs (before 20 <sup>th</sup> week of gestation); <i>Abbott Diagnostics, Abbott Park, IL</i>	euthyroid: 28.1 $\pm$ 5.3 hypothyroid: 28.4 $\pm$ 5.5 hyperthyroid: 30.0 $\pm$ 5.4 hypothyroxinemia: 30.0 $\pm$ 6.3 TPO-Ab-: 28.2 $\pm$ 5.4 TPO-Ab+: 28.6 $\pm$ 5.0	cardiometabolic risk factor: blood sampling	16	maternal age, smoking, parity, and overweight/obesity
20	Jolving et al. (2018), Denmark	cohort (2,618)	Dx of autoimmune hyperthyroidism/Graves' disease (ICD-8 codes: 242.00, 242.01, 242.08, 242.09; ICD-10 code: E05.0) or autoimmune hypothyroidism/Hashimoto's thyroiditis (ICD-8 code: 244.01; ICD-10 codes: E06.3, E06.3A and E06.3B) (within one year before delivery)	N.A.	15 disease groups covering major non-malignant somatic and psychiatric disease categories	> 5	sex of the child, year of birth, maternal age at birth, delivery mode, multiple births, birth order, preterm birth, small for gestational age, and maternal comorbidity of the outcome disease
21	Liu et al. (2018), Denmark	cohort (14,302)	Dx using ICD-8 codes: 243.99–244.09; or E03 and ICD-10 code E89.0; Rx using ATC: H03A; data from DNPR (before 5 years after delivery);	N.A.	asthma: Dx using ICD-10: J45 and J46; Rx using ATC codes of inhaled $\beta$ 2-agonists (R03AC02–04, -12, and -13), inhaled glucocorticoids	> 5	maternal age, primiparity, smoking during pregnancy, education status, income status, calendar year of birth, maternal diabetes, maternal asthma, paternal asthma at delivery, and



Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
					(R03BA01, -02 and -05), fixed-dose combination of inhaled $\beta$ 2-agonists and glucocorticoids (R03AK06 and -07), leukotriene receptor antagonists (R03DC03), and anti-IgE therapies (R03DX05)		the index child's age at observation during the study period
22	Modesto et al. (2015), Finland	cohort (3,873)	TFT: thyrotropin, FT4 (range 6.6 to 17.9 weeks, mean of 13.6 weeks gestation); <i>FT4 &amp; TSH: Vitros ECiimmunodiagnostic system; Ortho Clinical Diagnostics;</i> <i>TPO-Ab: Phadia 250; Thermo Scientific;</i>	30.0 $\pm$ 5.0	ADHD: Conner's Parent Rating Scale-Revised Short Form with ADHD index	range 7.5 to 10.5, mean (SD) of 8.1 (0.2)	child age, sex, and ethnic background and maternal educational level, age, history of smoking, psychopathologic symptoms during pregnancy, parity, marital status, household income, BMI and time of blood sampling in pregnancy
23	Oostenbroek et al. (2017), Netherland	cohort (2,000)	TFT: TSH, FT4, TPO-Ab (median of 12.9 weeks gestation); <i>FT4 &amp; TSH: Beckman Coulter Inc (Fullerton, California)</i> <i>TPO-Ab+: E-CK-96; ZenTech, Angleur, Belgium;</i>	hypothyroxinemic: 32.2 $\pm$ 4.4 non-hypothyroxinemic: 31.8 $\pm$ 4.3	ADHD: parent and teacher reports of SDQ using borderline clinical cut-off	range 5 to 6, mean (SD) of 5.1 (0.2)	ethnicity, years of education, pregnancy BMI, hypertension, smoking during pregnancy of at least 1 cigarette per day and anxiety level

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
24	Pakkila et al. (2013), Finland	cohort (3,673)	TFT: TSH, FT4, TPO-Ab (10.7 $\pm$ 2.8 weeks gestation) <i>Architect i2000 automatic analyzer (Abbott Diagnostics)</i>	N.A.	same serum thyroid biomarkers level as mothers: TFT	8	maternal continuous TPO-Ab levels
25	Pakkila et al. (2014), Finland	cohort (5,131)	TFT: TSH, FT4, TPO-Ab (10.7 $\pm$ 2.8 weeks gestation); <i>Abbott Architect i2000 method (Abbott Diagnostics)</i>	N.A.	ADHD: Parents reported Rutter B2 Scale-Finnish version	8	having more than two children in the family, maternal smoking, maternal education, and maternal age
26	Petersen et al. (2018), Denmark	cohort (1,270,079)	hypothyroidism: Dx based on ICD-8 243.99 and 244.00-244.09, ICD-10: E00, E03.0-E03.9 AND E89.0, excluding 244.02, E03.0A, E03.1B, and E03.4; Rx based on thyroid hormone, ACT: h03A hyperthyroidism: Dx based on ICD-8 as 242.00–242.29 and by ICD-10 as E05.0-E05.9, excluding E05.4, E05.8A, and E05.9A; Rx based on anti-thyroid medication, ACT: H03A (before and during pregnancy, and within 5 years after pregnancy)	N.A.	cerebral palsy: Dx through the Danish National Cerebral Palsy Registry	range 1 to 6	birth year, maternal age, maternal diabetes, and maternal socioeconomic status and smoking and alcohol consumption in pregnancy
27	Roman et al. (2013), Netherland	cohort (4,039)	TFT: TSH, FT4, TPO-Ab (range 5.9 to 7.913.4 $\pm$ 1.9 weeks gestation); <i>FT4&amp;TSH: Vitros ECI Immunodiagnostic System;</i>	31.2 $\pm$ 4.7	ASD: parents reported CBCL using pervasive developmental problems scale	6	child's sex, ethnicity, gestational age at birth, birth weight, maternal age, educational level, smoking history, prenatal psychopathology, thyroid

Item	Author (Year), Country	Study design (Sample size)	Exposure measurement <sup>a</sup> (Timing), Measurement kit for laboratory assays	Mean maternal age (years $\pm$ SD)	Outcome measurement <sup>b</sup>	Age of children (years)	Adjusted variables in the model
			<i>Ortho Clinical Diagnostics, Rochester, NY; TPO-Ab: Phadia 250 immunoassay; Phadia, Uppsala, Sweden;</i>				medication during pregnancy, parity, marital status, maternal folate and C-reactive protein levels in early pregnancy, time of thyroid sampling during pregnancy, and paternal age.
28	Vermiglio et al. (2004), Italy	cohort (27)	TFT: TSH, FT4 (5 to 10, 11 to 14, 18 to 20 weeks gestation)	N.A.	ADHD: DMS-IV-TR items by clinical observation	range 8 to 10	no adjusted covariate
29	Wasserman et al. (2008), U.S.	cohort (1,731)	TFT: TPO-Ab (3 <sup>rd</sup> trimester) ; <i>QUANTA Lite TPO; INOVA Diagnostics, San Diego, California</i>	24.1 (range: 11 to 46)	sensorineural hearing loss: Dx according to pediatric case definition	8	maternal age, race and treated clinical hypothyroidism

<sup>a</sup> Exposure refers to maternal thyroid status. Timing refers to the time of the diagnosis or prescription or the function test conducted. TFT indicates thyroid function test; Dx indicates the diagnosis of thyroid diseases; Rx indicates prescription for thyroid diseases;

<sup>b</sup> Outcomes refer to diagnosed or assessed disorders in the offspring. Dx indicates diagnosis and Rx indicates prescriptions;

Abbreviations: ADHD, attention deficit hyperactivity disorder; ADI-R, Autism Diagnostic Interview-Revised; ASD, autism spectrum disorders; ATC: Anatomical Therapeutic Chemical Classification System; BMI: Body Mass Index; CBCL, Child Behavior Checklists; CHD: congenital heart defect; DAWBA, Developmental and Well-Being Assessment; DMS-IV-TR, Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition- Text Revision; DNHR, Danish National Hospital Registry; DNPR, Danish National Prescription Registry, DPCR, Danish Psychiatric Central Register; FHDR, Finnish Hospital, and Outpatient Discharge Registry; FT4, free thyroxine; ICD: International Classification of Diseases; KCPT: Kiddie Continuous Performance Test; MBRN: Medical Birth Registry of Norway; NorPD: Norwegian Prescription Database; N.A., not available.; SD: Standard deviation; SDQ: Strengths and Difficulties Questionnaire; SUMC, Soroka University Medical Center; TgAb, thyroglobin antibodies; TPO-Ab(+/-), thyroid peroxidase antibodies (positive / negative); TSH, thyroid stimulating hormone; WISC-III: Wechsler Intelligence Scale for Children- Third edition

**Table 2. Estimated associations between maternal hyperthyroidism and offspring neurodevelopmental disorders**

<b>Item</b>	<b>Author (year)</b>	<b>Outcome measurement</b>	<b>Estimate (95% CI)</b>
<i>ADHD as outcome</i>			
<b>1</b>	Andersen et al. (2014)	ICD-10 diagnosis and prescription of drugs	HR = 1.18 (1.03, 1.36)
<b>2</b>	Instanes et al. (2017)	Prescription of drugs	OR = 1.2 (0.9, 1.5)
<i>ASD as outcome</i>			
<b>1</b>	Andersen et al. (2014)	ICD-10 diagnosis	HR = 1.18 (0.96, 1.45)
<b>2</b>	Brown et al. (2015)	ICD-10 diagnosis assessed with the Autism Diagnostic Interview-Revised	OR = 1.06 (0.54, 2.10)
<i>Epilepsy as outcome</i>			
<b>1</b>	Andersen et al. (2013)	ICD-10 diagnosis	HR = 1.20 (1.09, 1.32)
<b>2</b>	Jolving et al. (2018)	ICD-10 diagnosis	HR = 1.04 (0.70, 1.55)
<i>Cerebral palsy as outcome</i>			
<b>1</b>	Petersen et al. (2018)	ICD-8 and ICD-10 diagnosis	OR = 1.11 (0.94, 1.66)
<i>Schizophrenia as outcome</i>			
<b>1</b>	Gyllenberg et al. (2016)	ICD-10 diagnosis	OR = 0.87 (0.41, 1.82)
<b>2</b>	Jolving et al. (2018)	ICD-10 diagnosis	HR = 1.13 (0.43, 3.01)

**Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorders; ICD: International Classification of Diseases**

**Table 3. Estimated associations between maternal hypothyroidism and offspring neurodevelopmental disorders**

Item	Author (year)	Outcome measurement	Estimate (95% CI)
<i>ADHD as outcome</i>			
1	Andersen et al. (2014)	Prescription of drugs	HR = 1.10 (0.98, 1.25)
2	Gutvirtz et al. (2018)	ICD-9 diagnosis	HR = 2.25 (0.31, 16.16)
3	Haddow et al. (1999) <sup>a</sup>	Conner's Continuous Performance Test > 8 <sup>a</sup>	OR = 3 (1, 5)
		WISC-III freedom from distractibility score <sup>b</sup>	Mean difference $\pm$ SE = -3 $\pm$ 2
4	Instanes et al. (2017)	Prescription of drugs	OR = 1.2 (1.0, 1.4)
<i>ASD as outcome</i>			
1	Andersen et al. (2014)	ICD-10 diagnosis	HR = 1.30 (1.11, 1.53)
2	Brown et al. (2015)	ICD-10 diagnosis assessed with the Autism Diagnostic Interview-Revised	OR = 0.67 (0.27, 1.63)
3	Getahun et al. (2018)	Clinical diagnosis	HR = 1.31 (1.13, 1.53)
4	Gutvirtz et al. (2018)	ICD-9 diagnosis	HR = 5.22 (0.70, 38.56)
5	George et al. (2014)	Clinical diagnosis	OR = 4.25 (1.38, 13.07)
<i>Epilepsy as outcome</i>			
1	Andersen et al. (2013)	ICD-10 diagnosis	HR = 1.22 (1.06, 1.40)
2	Jolving et al. (2018)	ICD-10 diagnosis	HR = 0.94 (0.39, 2.27)
<i>Language and speech impairment as outcome</i>			
1	Frank et al. (2019)	ICD-10 diagnosis	HR = 0.75 (0.38, 1.43)
<i>Schizophrenia as outcome</i>			
1	Gyllenberg et al. (2016)	ICD-10 diagnosis	OR = 0.86 (0.23, 3.24)
2	Jolving et al. (2018)	ICD-10 diagnosis	HR = 10.64 (2.80, 40.41)
<i>Cerebral palsy as outcome</i>			
1	Gutvirtz et al. (2018)	ICD-9 diagnosis	HR = 0.88 (0.13, 6.31)
2	Petersen et al. (2018)	ICD diagnosis	OR = 0.95 (0.64, 1.39)

Haddow et al. used Continuous Performance Test score and WISC-III freedom-from-distractibility score to measure offspring ADHD. <sup>a</sup> A higher score indicates more problems in this scale. The author took score 8 as cut-off point and this row provides OR for the children of

mothers with hypothyroidism as compared with the control children; <sup>b</sup> This row provides the difference as the value in the case minus the average of the values in the control; the value expressed as means  $\pm$  SE of the individual differences in each matched set;

**Abbreviations:** ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorders; ICD: International Classification of Diseases; WISC-III: Wechsler Intelligence Scale for Children- Third edition

**Table 4. Estimated associations between maternal hypothyroxinemia and offspring neurodevelopmental disorders**

Item	Author (year)	Definition of maternal hypothyroxinemia	Outcome measurement	Estimate (95% CI)
<i>ADHD as outcome</i>				
1	Modesto et al. (2015)	TSH levels of 0.1 to 2.5 mIU/L and FT4 levels below the 5 <sup>th</sup> percentile of the sample	Conner's Parent Rating Scale-Revised Short Form	$\beta = 0.07$ (0.003, 0.14)
2	Oostenbroek et al. (2017)	FT4 level below the 10 <sup>th</sup> or 5 <sup>th</sup> percentile of distribution in the maternal FT4 level	Strengths and Difficulties Questionnaire	Teacher-reported: OR <sub>FT4 &lt; 10<sup>th</sup> percentile</sub> = 1.47 (0.99, 2.20) OR <sub>FT4 &lt; 5<sup>th</sup> percentile</sub> = 1.70 (1.01, 2.86) Parent-reported: OR <sub>FT4 &lt; 10<sup>th</sup> percentile</sub> = 0.85 (0.50, 1.46) OR <sub>FT4 &lt; 5<sup>th</sup> percentile</sub> = 0.78 (0.36, 1.66)
3	Vermiglio et al. (2004)	normal TSH concentrations (0.4 - 4.0 $\mu$ U/ml) with low serum FT4 value as compared with the range values calculated at the same stage of pregnancy	DMS-IV-TR items by clinical observation	$\chi^2 = 2.34, p = 0.01$
<i>ASD as outcome</i>				
1	Roman et al. (2013)	mild: normal TSH levels of 0.03 to 2.5 mIU/L and FT4 levels below the 10 <sup>th</sup> percentile of the sample (< 11.82 pmol/L); severe: FT4 levels below the 5 <sup>th</sup> percentile of the sample (< 10.99 pmol/L)	Pervasive Developmental Problems subscale from CBCL	OR <sub>FT4 &lt; 10<sup>th</sup> percentile</sub> = 1.41 (0.78, 2.57) OR <sub>FT4 &lt; 5<sup>th</sup> percentile</sub> = 2.60 (1.30, 5.18)
<i>Schizophrenia as outcome</i>				
1	Gyllenberg et al. (2016)	TSH levels over 5 <sup>th</sup> to 95 <sup>th</sup> percentile and FT4	ICD-10 diagnosis	OR = 1.75 (1.22, 2.50)

		levels below 10 <sup>th</sup> percentile of the sample		
--	--	---	--	--

**Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorders; CBCL, Child Behavior Checklists; DMS-IV-TR, Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition- Text Revision; FT4, free thyroxine; TSH, thyroid stimulating hormone**



**Table 5. Estimated associations between maternal thyroid hormone parameters and offspring neurodevelopmental disorders**

Item	Author (year)	Outcome measurement	Estimate (95% CI)
<b>Maternal TPO-Ab+</b>			
<i>ADHD as outcome</i>			
1	Fetene et al. (2018)	DAWBA	OR = 1.00 (0.84, 1.20) per SD
2	Ghassabian et al. (2012)	CBCL (Maternal and paternal rating)	OR = 1.77 (1.15, 2.72), TPO-Ab+ defined as >100 IU/ml
<i>ASD as outcome</i>			
1	Brown et al. (2015) <sup>a</sup>	ICD-10 diagnosis	OR = 1.78 (1.16, 2.75), TP-Ab+ defined as >156 IU/ml
2	Roman et al. (2013) <sup>b</sup>	Pervasive Developmental Problems subscale from CBCL	OR = 0.78 (0.28, 2.16), TPO-Ab+ defined as >100 IU/ml
<i>Depression as outcome</i>			
1	Fetene et al. (2019)	DAWBA	OR = 1.02 (0.85, 1.23) per SD
<b>Maternal FT4 level</b>			
<i>ADHD as outcome</i>			
1	Chevrier et al. (2011)	CBCL	$\beta = -0.10 (-2.03, 1.82)$ per 1 ng/dL
		KCPT	$\beta = 7.52 (-4.86, 19.91)$ per 1 ng/dL
2	Modesto et al. (2015)	Conner's Parent Rating Scale-Revised Short Form	$\beta = -0.01 (-0.02, 0.01)$ per SD
3	Fetene et al. (2018)	DAWBA	OR = 1.10 (0.89, 1.36) per SD
4	Oostenbroek et al. (2017)	SDQ	Teacher-reported: OR = 0.95 (0.85, 1.05) per 1 pmol/L Parent-reported: OR = 1.01 (0.90, 1.13) per 1 pmol/L
<i>ASD as outcome</i>			
1	Roman et al. (2013)	Pervasive Developmental Problems subscale from CBCL	OR = 0.95 (0.77, 1.17) per SD
<i>Depression as outcome</i>			
1	Fetene et al. (2019)	DAWBA	OR = 1.21 (1.00, 1.47) per SD
<i>Schizophrenia as outcome</i>			
1	Gyllenberg et al. (2016)	ICD-10 diagnosis	OR = 0.54 (0.31, 0.94) per LN unit

Maternal TSH level			
<i>ADHD as outcome</i>			
1	Chevrier et al. (2011)	CBCL	$\beta = -0.65 (-1.26, -0.04)$ per LN unit
		KCPT	$\beta = -0.75 (-4.61, 3.12)$ per LN unit
2	Ghassabian et al. (2011)	CBCL	$\beta = 0.08 (0.01, 0.15)$ per SD
3	Modesto et al. (2015)	Conner's Parent Rating Scale-Revised Short Form	$\beta = -0.01 (-0.02, 0.01)$ per SD
4	Fetene et al. (2018)	DAWBA	OR = 0.83 (0.37, 1.85) per SD
5	Oostenbroek et al. (2017)	SDQ	Teacher-reported: OR = 1.02 (0.96, 1.09) per mU/L Parent-reported: OR = 1.01 (0.92, 1.11) per mU/L
6	Pakkila et al. (2014)	Rutter B2 Scale-Finnish version	OR <sub>boys</sub> = 1.17 (1.00, 1.36) per LN unit OR <sub>girls</sub> = 1.39 (1.07, 1.80) per LN unit
<i>ASD as outcome</i>			
1	Roman et al. (2013)	Pervasive Developmental Problems subscale from CBCL	OR = 0.92 (0.72, 1.17) per SD
<i>Depression as outcome</i>			
1	Fetene et al. (2019)	DAWBA	OR = 1.14 (0.98, 1.32) per SD
<i>Schizophrenia as outcome</i>			
1	Gyllenberg et al. (2016)	ICD-10 diagnosis	OR= 0.93 (0.84, 1.02) per LN unit

<sup>a</sup>. The cut-off point for TPO-Ab+ corresponded to serum concentrations >156 IU/ml

<sup>b</sup>. The cut-off point for TPO-Ab+ corresponded to plasma concentrations  $\geq 100$  IU/ml

**Abbreviations:** ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorders; CBCL, Child Behavior Checklist; DAWBA: Developmental and Well-Being Assessment; FT4, free thyroxine; SDQ: Strengths and Difficulties Questionnaire; TPO-Ab: thyroid peroxidase antibodies; TSH, thyroid stimulating hormone

## References:

1. Carney LA, Quinlan JD, West JM. Thyroid disease in pregnancy. *Am Fam Physician*. 2014;89(4):273-278.
2. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2012;97(8):2543-2565.
3. Mestman JH. Hyperthyroidism in pregnancy. *Current opinion in endocrinology, diabetes, and obesity*. 2012;19(5):394-401.
4. Stagnaro-Green A, Pearce E. Thyroid disorders in pregnancy. *Nature Reviews Endocrinology*. 2012;8(11):650-658.
5. Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. *BMJ*. 2008;336(7645):663-667.
6. Lazarus JH. Thyroid function in pregnancy. *Br Med Bull*. 2011;97:137-148.
7. Gartner R. Thyroid diseases in pregnancy. *Current opinion in obstetrics & gynecology*. 2009;21(6):501-507.
8. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. *Thyroid*. 2017;27(3):315-389.
9. Lazarus JH. Thyroid dysfunction in pregnancy: Offspring effects. *The Lancet Diabetes and Endocrinology*. 2013;1(3):174-175.
10. Moog NK, Entringer S, Heim C, Wadhwa PD, Kathmann N, Buss C. Influence of maternal thyroid hormones during gestation on fetal brain development. *Neuroscience*. 2017;342:68-100.
11. Pop VJ, de Vries E, van Baar AL, et al. Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? *J Clin Endocrinol Metab*. 1995;80(12):3561-3566.
12. Sahay RK, Nagesh VS. Hypothyroidism in pregnancy. *Indian J Endocrinol Metab*. 2012;16(3):364-370.
13. Andersen SL, Carle A, Karmisholt J, Pedersen IB, Andersen S. MECHANISMS IN ENDOCRINOLOGY: Neurodevelopmental disorders in children born to mothers with thyroid dysfunction: evidence of fetal programming? *European journal of endocrinology*. 2017;177(1):R27-r36.
14. Jolving LR, Nielsen J, Kesmodel US, Nielsen RG, Norgard BM, Beck-Nielsen SS. Chronic diseases in the children of women with maternal thyroid dysfunction: a nationwide cohort study. *Clin Epidemiol*. 2018;10:1381-1390.
15. Andersen SL, Andersen S, Vestergaard P, Olsen J. Maternal Thyroid Function in Early Pregnancy and Child Neurodevelopmental Disorders: A Danish Nationwide Case-Cohort Study. *Thyroid*. 2018;28(4):537-546.
16. Eshkoli T, Wainstock T, Sheiner E, Beharier O, Fraenkel M, Walfisch A. Maternal Hypothyroidism during Pregnancy and the Risk of Pediatric Endocrine Morbidity in the Offspring. *American Journal of Perinatology*. 2019;36(9):975-980.
17. Pakkila F, Mannisto T, Surcel HM, et al. Maternal thyroid dysfunction during pregnancy and thyroid function of her child in adolescence. *J Clin Endocrinol Metab*. 2013;98(3):965-972.
18. Grattan MJ, Thomas DS, Hornberger LK, Hamilton RM, Midodzi WK, Vohra S. Maternal hypothyroidism may be associated with CHD in offspring. *Cardiology in the Young*. 2014;25(7):1247-1253.
19. Heikkinen AL, Pakkila F, Hartikainen AL, Vaarasmaki M, Mannisto T, Suvanto E. Maternal Thyroid Antibodies Associates With Cardiometabolic Risk Factors in Children at the Age of 16. *J Clin Endocrinol Metab*. 2017;102(11):4184-4190.
20. Liu X, Andersen SL, Olsen J, et al. Maternal hypothyroidism in the perinatal period and childhood asthma in the offspring. *Allergy*. 2018;73(4):932-939.

21. Cowett RM, Stern L. Maternal thyroid status and the incidence of respiratory distress syndrome: evaluation of a proposed relationship. *Pediatrics*. 1975;55(4):497-499.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
23. Ge GM. Maternal thyroid dysfunction and adverse outcomes in the offspring 2020 <https://osf.io/k9jpf> Accessed July 14, 2020.
24. Andersen SL, Laurberg P, Wu CS, Olsen J. Maternal thyroid dysfunction and risk of seizure in the child: a Danish nationwide cohort study. *J Pregnancy*. 2013;2013:636705.
25. Andersen SL, Laurberg P, Wu CS, Olsen J. Attention deficit hyperactivity disorder and autism spectrum disorder in children born to mothers with thyroid dysfunction: a Danish nationwide cohort study. *BJOG*. 2014;121(11):1365-1374.
26. Brown AS, Surcel HM, Hinkka-Yli-Salomaki S, Cheslack-Postava K, Bao Y, Sourander A. Maternal thyroid autoantibody and elevated risk of autism in a national birth cohort. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015;57:86-92.
27. George B, Padmam MS, Nair MK, Leena ML, Russell PS. CDC Kerala 13: Antenatal, natal and postnatal factors among children (2-6 y) with autism--a case control study. *Indian J Pediatr*. 2014;81 Suppl 2:S133-137.
28. Gyllenberg D, Sourander A, Surcel HM, Hinkka-Yli-Salomaki S, McKeague IW, Brown AS. Hypothyroxinemia During Gestation and Offspring Schizophrenia in a National Birth Cohort. *Biol Psychiatry*. 2016;79(12):962-970.
29. Instanes JT, Halmoy A, Engeland A, Haavik J, Furu K, Klungsoyr K. Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases. *Biological Psychiatry*. 2017;81(5):452-459.
30. Chevrier J, Harley KG, Kogut K, Holland N, Johnson C, Eskenazi B. Maternal Thyroid Function during the Second Half of Pregnancy and Child Neurodevelopment at 6, 12, 24, and 60 Months of Age. *J Thyroid Res*. 2011;2011:426427.
31. Fetene DM, Betts KS, Alati R. The role of maternal prenatal thyroid function on offspring depression: Findings from the ALSPAC cohort. *Development and psychopathology*. 2019:1-8.
32. Fetene DM, Betts KS, Alati R. Maternal Prenatal Thyroid Function and Offspring ADHD: Findings from the ALSPAC Cohort. *Journal of Nervous and Mental Disease*. 2018;206(11):859-864.
33. Frank AS, Lupattelli A, Brandlistuen RE, Nordeng H. Maternal Thyroid Hormone Replacement Therapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. *JAMA Netw Open*. 2019;2(10):e1912424.
34. Getahun D, Jacobsen SJ, Fassett MJ, et al. Association between maternal hypothyroidism and autism spectrum disorders in children. *Pediatr Res*. 2018;83(3):580-588.
35. Ghassabian A, Bongers-Schokking JJ, Henrichs J, et al. Maternal thyroid function during pregnancy and behavioral problems in the offspring: the generation R study. *Pediatr Res*. 2011;69(5 Pt 1):454-459.
36. Ghassabian A, Bongers-Schokking JJ, de Rijke YB, et al. Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. *Thyroid*. 2012;22(2):178-186.
37. Gutvitz G, Walfisch A, Wainstock T, Landau D, Sheiner E. Maternal hypothyroidism and future pediatric neurological morbidity of the offspring. *Archives of Gynecology and Obstetrics*. 2019.
38. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *New England Journal of Medicine*. 1999;341(8):549-555.
39. Modesto T, Tiemeier H, Peeters RP, et al. Maternal mild thyroid hormone insufficiency in early pregnancy and attention-deficit/hyperactivity disorder symptoms in children. *JAMA Pediatrics*. 2015;169(9):838-845.

40. Oostenbroek MHW, Kersten RHJ, Tros B, Kunst AE, Vrijkotte TGM, Finken MJJ. Maternal hypothyroxinaemia in early pregnancy and problem behavior in 5-year-old offspring. *Psychoneuroendocrinology*. 2017;81:29-35.
41. Pakkila F, Mannisto T, Pouta A, et al. The impact of gestational thyroid hormone concentrations on ADHD symptoms of the child. *J Clin Endocrinol Metab*. 2014;99(1):E1-8.
42. Petersen TG, Andersen AN, Uldall P, et al. Maternal thyroid disorder in pregnancy and risk of cerebral palsy in the child: a population-based cohort study. *BMC Pediatr*. 2018;18(1):181.
43. Roman GC, Ghassabian A, Bongers-Schokking JJ, et al. Association of gestational maternal hypothyroxinemia and increased autism risk. *Ann Neurol*. 2013;74(5):733-742.
44. Vermiglio F, Lo Presti VP, Moleti M, et al. Attention deficit and hyperactivity disorders in the offspring of mothers exposed to mild-moderate iodine deficiency: a possible novel iodine deficiency disorder in developed countries. *J Clin Endocrinol Metab*. 2004;89(12):6054-6060.
45. Wasserman EE, Nelson K, Rose NR, et al. Maternal thyroid autoantibodies during the third trimester and hearing deficits in children: an epidemiologic assessment. *Am J Epidemiol*. 2008;167(6):701-710.
46. Rotem RS, Chodick G, Shalev V, et al. Maternal Thyroid Disorders and Risk of Autism Spectrum Disorder in Progeny. *Epidemiology*. 2020;31(3):409-417.
47. Wiles KS, Jarvis S, Nelson-Piercy C. Are we overtreating subclinical hypothyroidism in pregnancy? *Bmj*. 2015;351:h4726.
48. Maraka S, Mwangi R, McCoy RG, et al. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. *bmj*. 2017;356:i6865.
49. Casey BM, Thom EA, Peaceman AM, et al. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. *N Engl J Med*. 2017;376(9):815-825.
50. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *European thyroid journal*. 2014;3(2):76-94.
51. Preau L, Fini JB, Morvan-Dubois G, Demeneix B. Thyroid hormone signaling during early neurogenesis and its significance as a vulnerable window for endocrine disruption. *Biochimica et Biophysica Acta - Gene Regulatory Mechanisms*. 2015;1849(2):112-121.
52. Glinioer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocrine reviews*. 1997;18(3):404-433.
53. Krassas G, Poppe K, Glinioer D. Thyroid function and human reproductive health. *Endocrine reviews*. 2010;31(5):702-755.
54. Marco A, Vicente A, Castro E, et al. Patterns of iodine intake and urinary iodine concentrations during pregnancy and blood thyroid-stimulating hormone concentrations in the newborn progeny. *Thyroid*. 2010;20(11):1295-1299.
55. Fan X, Wu L. The impact of thyroid abnormalities during pregnancy on subsequent neuropsychological development of the offspring: a meta-analysis. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2016;29(24):3971-3976.
56. Wang P, Gao J, Zhao S, Guo Y, Wang Z, Qi F. Maternal Thyroxine Levels During Pregnancy and Outcomes of Cognitive Development in Children. *Molecular neurobiology*. 2016;53(4):2241-2248.
57. Thompson W, Russell G, Baragwanath G, Matthews J, Vaidya B, Thompson-Coon J. Maternal thyroid hormone insufficiency during pregnancy and risk of neurodevelopmental disorders in offspring: A systematic review and meta-analysis. *Clinical endocrinology*. 2018;88(4):575-584.
58. Fetene DM, Betts KS, Alati R. MECHANISMS IN ENDOCRINOLOGY: Maternal thyroid dysfunction during pregnancy and behavioural and psychiatric disorders of children: a systematic review. *European journal of endocrinology*. 2017;177(5):R261-r273.

59. Drover SSM, Villanger GD, Aase H, et al. Maternal Thyroid Function during Pregnancy or Neonatal Thyroid Function and Attention Deficit Hyperactivity Disorder: A Systematic Review. *Epidemiology*. 2019;30(1):130-144.
60. Rao M, Zeng Z, Zhou F, et al. Effect of levothyroxine supplementation on pregnancy loss and preterm birth in women with subclinical hypothyroidism and thyroid autoimmunity: a systematic review and meta-analysis. *Hum Reprod Update*. 2019;25(3):344-361.
61. Sun X, Hou N, Wang H, Ma L, Sun J, Liu Y. A Meta-Analysis of Pregnancy Outcomes With Levothyroxine Treatment in Euthyroid Women With Thyroid Autoimmunity. *J Clin Endocrinol Metab*. 2020;105(4).